Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: A randomized triple blind placebo controlled study

Pharmacopsychiatry

Volumn 47, Issue 4-5, 2014, Pages 156-161

  Fadai, F ^a   Mousavi, B ^a   Ashtari, Z ^a   Ali Beigi, N ^a   Farhang, S ^b   Hashempour, S ^a   Shahhamzei, N ^c   Zahra Bathaie, S ^c,d  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FBS; insulin resistance; metabolic syndrome; olanzapine; saffron

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; CROCIN; CROCUS SATIVUS EXTRACT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; OLANZAPINE; PLACEBO; SAFFRON AQUEOUS EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; CAROTENOID; GLUCOSE BLOOD LEVEL; NEUROLEPTIC AGENT; PLANT EXTRACT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG SAFETY; DSM-IV-TR; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROCAPSULE; MORBIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; STRUCTURED INTERVIEW; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; ADOLESCENT; CHEMICALLY INDUCED; CROCUS; DOUBLE BLIND PROCEDURE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; CAROTENOIDS; CROCUS; DOUBLE-BLIND METHOD; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLANT EXTRACTS; SCHIZOPHRENIA; WAIST CIRCUMFERENCE;

EID: 84904789960     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0034-1382001     Document Type: Article

References (45)

1. Hert M., Schreurs V., Vancampfort D. et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry: 2009; 8 15 22
2. Goff D. C., Sullivan L. M., McEvoy J. P. et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizoph Res: 2005; 80 45 53 (Pubitemid 41587462)
3. Meyer J., Koro C. E., Italien GJ. The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry: 2005; 17 173 180 (Pubitemid 40827294)
4. Hennekens C. H., Hennekens A. R., Hollar D. et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J: 2005; 150 1115 1121 (Pubitemid 41773510)
5. Baptista T., Kin N. M., Beaulieu S. et al. obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. pharmacopsychiatry: 2002; 35 205 219 (Pubitemid 36061310)
6. Newcomer JW. Second-generation [atypical] antipsychotics and metabolic effects. CNS Drugs: 2005; 19 1 93
7. Tschoner A., Engl J., Laimer M. et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract: 2007; 61 1356 1370 (Pubitemid 47052363)
8. Nasrallah H. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry: 2008; 13 27 35 (Pubitemid 350275185)
9. Scheen A., De Hert M. Drug-induced diabetes mellitus: the example of atypical antipsychotics. Rev médic Liège: 2005; 60 455
10. Scheen A., De Hert M. Abnormal glucose metabolism in patients treated with antipsychotics. Diab Metab: 2007; 33 169 175 (Pubitemid 46876639)
11. Van Winkel R., De Hert M., Wampers M. et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry: 2008; 69 472
12. Meyer J. M., Pandina G., Bossie C. A. et al. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Therapeut: 2005; 27 1930 1941 (Pubitemid 43293215)
13. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry: 2007; 68 04 8 13 (Pubitemid 46762118)
14. Conn P. J., Lindsley C. W., Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci: 2009; 30 25 31
15. Mauri M., Simoncini M., Castrogiovanni S. et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry: 2008; 41 17 23 (Pubitemid 351195888)
16. Kristiansen L. V., Huerta I., Beneyto M. et al. NMDA receptors and schizophrenia. Curr Opin Pharmacol: 2007; 7 48 55
17. Shirali S., Bathaie S. Z., Nakhjavani M. et al. Effects of saffron [Crocus sativus L.] aqueous extract on serum biochemical factors streptozotocin-induced diabetic rats. Iran J Med Arom Plants: 2012; 28 293 308
18. Ghahghaei A., Bathaie S. Z., Kheirkhah H. et al. The protective effect of crocin on the amyloid fibril formation of AB42 peptide in vitro. Cell Mol Biol Lett: 2013; 1 12
19. Shirali S., Zahra Bathaie S., Nakhjavani M. Effect of crocin on the insulin resistance and lipid profile of streptozotocin-induced diabetic rats. Phytother Res: 2013; 27 1042 1047
20. Akhondzadeh Basti A., Moshiri E., Noorbala A. A. et al. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsycho pharmacol Biol Psychiatry: 2007; 31 439 442 (Pubitemid 46209441)
21. Akhondzadeh S., Sabet M. S., Harirchian M. H. et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther: 2010; 35 581 588
22. Mousavi S. Z., Bathaie SZ. Historical uses of saffron: Identifying potential new avenues for modern research. Avicenna J Phytomed: 2011; 1 57 66
23. Bathaie S. Z., Mousavi SZ. New applications and mechanisms of action of saffron and its important ingredients. Crit Rev Food Sci Nutr: 2010; 50 761 786
24. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-IV-TR®. American Psychiatric Pub. 2000
25. Turner R., Levy J., Rudenski A. et al. Measurement of insulin resistance and beta-cell function: the HOMA and CIGMA approach. Front Diab: 1993; 12 66 75
26. National Institute of Health Third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults [Adult Treatment Panel III]. NIH Publ: 2001; 1 3670
27. Modaghegh M. H., Shahabian M., Esmaeili H. A. et al. Safety evaluation of saffron [Crocus sativus] tablets in healthy volunteers. Phytomedicine: 2008; 15 1032 1037
28. th Edition. London, Routledge 2011
29. Druss B. G., Bradford W. D., Rosenheck R. A. et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry: 2001; 58 565
30. Richards M., Chiba S., Ninomiya M. et al. Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80. Pharmacopsychiatry: 2013; 46 267 273
31. Anderson G., Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis: 2012; 27 113 119
32. Chen C-H, Chiu C-C, Huang M-C et al. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Progr Neuro-Psychopharmacol Biol Psychiatry: 2008; 32 925 931 (Pubitemid 351609224)
33. Mohamadpour A. H., Ayati Z., Parizadeh M. R. et al. Safety evaluation of crocin [a constituent of saffron] tablets in healthy volunteers. Iran J Basic Med Sci: 2013; 16 39
34. Shahmansouri N., Farokhnia M., Abbasi S-H et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord: 2014; 155 216 222
35. Boskabady M. H., Ghasemzadeh Rahbardar M., Nemati H. et al. Inhibitory effect of Crocus sativus [saffron] on histamine [H1] receptors of guinea pig tracheal chains. Pharmazie: 2010; 65 300 305
36. Xi L., Qian Z. Y., Shen X. C. et al. Crocetin prevents dexamethasone-induced insulin resistance in rats. Planta Med: 2005; 71 917 922 (Pubitemid 41658567)
37. Asai A., Nakano T., Takahashi M. et al. Orally administered crocetin and crocins are absorbed into blood plasma as crocetin and its glucuronide conjugates in mice. J Agric Food Chem: 2005; 53 7302 7306 (Pubitemid 41375350)
38. Xi L., Qian Z., Du P. et al. Pharmacokinetic properties of crocin [crocetin digentiobiose ester] following oral administration in rats. Phytomedicine: 2007; 14 633 636 (Pubitemid 47189641)
39. Chryssanthi D. G., Lamari F. N., Georgakopoulos C. D. et al. A new validated SPE-HPLC method for monitoring crocetin in human plasma - application after saffron tea consumption. J Pharm Biomed Anal: 2011; 55 563 588
40. Praharaj S. K., Jana A. K., Goyal N. et al. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol: 2011; 71 377 382
41. Baptista T., Rangel N., Fernández V. et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial. Schizoph Res: 2007; 93 99 108 (Pubitemid 46839067)
42. Wozniak J., Mick E., Waxmonsky J. et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adol Psychopharmacol: 2009; 19 539 545
43. Narula P. K., Rehan H. S., Unni KE S. et al. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial. Schizoph Res: 2010; 118 218 223
44. Ellinger L. K., Ipema H. J., Stachnik JM. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic- induced weight gain. Ann Pharmacother: 2010; 44 668 679
45. Kanner A. M., Wuu J., Faught E. et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilep Behav: 2003; 4 548 552 (Pubitemid 37407613)